GSK continues to invest heavily in Belgium at its sites in Wavre and Rixensart
The British pharmaceutical company GSK continues to invest in its production site in Wavre and its research and development site in Rixensart.
In Wavre, the largest vaccine production centre in the world, the €330 million investment announced in March 2021 includes the creation of a new freeze-drying unit. GSK wants to make its Wavre site a place of expertise for the production of freeze-dried vaccines. The Group is also expanding its technical research and development building.
In Rixensart, the €100 million investment announced at the end of 2020, aims to consolidate and centralize the company’s research and development activities in a modern building for the long term. The site will also have new laboratories, modular equipment to ensure innovation and R&D performance, and an automated system to facilitate the management and analysis of clinical samples arriving in Rixensart from all over the world, and the encoding of results.
These sums are on top of the €600 million already secured over the past two years for the Belgian sites in both Rixensart and Wavre, and illustrate GSK’s confidence in its Belgian operations and people.